Pierone G, Schulman KL, Fusco J, et al. Comparison of a Two-Drug Regimen (Dolutegravir/Rilpivirine) to Standard Three-Drug Regimens in Virologically Suppressed, Treatment Experienced Individuals in the Real World [PE2/37]. Presented at: 17th European AIDS Conference (EACS 2019) 2019; Basel, Switzerland
Research Category: Abstracts and Posters
Virologic Failure In ART-Naïve Patients Initiating on a Dolutegravir- or Elvitegravir-Based Regimen
Wohlfeiler MB, Schulman KL, Fusco J, et al. Virologic Failure In ART-Naïve Patients Initiating on a Dolutegravir- or Elvitegravir-Based Regimen. Presented at: IDWeek 2019; Washington, DC, USA
Risk of type-2 diabetes mellitus after initiating integrase and protease inhibitors in individuals living with HIV in the United States
Hsu R, Brunet L, Fusco J, et al. Risk of type-2 diabetes mellitus after initiating integrase and protease inhibitors in individuals living with HIV in the United States [341]. Paper presented at: IDWeek 2019; Washington, DC, USA
Switching from TDF to TAF: Missed Opportunities for Statin Use in HIV
Mallon P, Brunet L, Fusco J, et al. Switching from TDF to TAF: Missed Opportunities for Statin Use in HIV [337]. Presented at: IDWeek 2019; Washington, DC, USA.
Characteristics and Outcomes Over First 12 Months of a Two-Drug Regimen (Dolutegravir/Rilpivirine) for Treatment of HIV-1 in the United States
Pierone G, Schulman KL, Fusco J, et al. Characteristics and Outcomes Over First 12 Months of a Two-Drug Regimen (Dolutegravir/Rilpivirine) for Treatment of HIV-1 in the United States [2483]. Presented at: IDWeek 2019; Washington, DC, USA
TDF/FTC Pre-Exposure Prophylaxis (PrEP) from 2012 to 2018 in the OPERA Cohort
Mounzer K, Fusco J, Hsu R, et al. TDF/FTC Pre-Exposure Prophylaxis (PrEP) from 2012 to 2018 in the OPERA Cohort. Presented at: 10th IAS Conference on HIV Science 2019; Mexico City, Mexico.
Gastrointestinal Disorders Following Initiation of Dolutegravir, Elvitegravir, Raltegravir or Darunavir
Mounzer K, Brunet L, Fusco J, et al. Gastrointestinal Disorders Following Initiation of Dolutegravir, Elvitegravir, Raltegravir or Darunavir. Presented at: 10th IAS Conference on HIV Science 2019; Mexico City, Mexico
Renal Function with Dolutegravir, Elvitegravir/Cobicistat, Raltegravir or Darunavir
Hsu R, Brunet L, Fusco J, et al. Renal Function with Dolutegravir, Elvitegravir/Cobicistat, Raltegravir or Darunavir. Paper presented at: 10th IAS Conference on HIV Science 2019; Mexico City, Mexico
Virologic Outcomes among Treatment-Naïve HIV+ Patients Initiating Common First Antiretroviral Therapy Core Agents in the OPERA Observational Database
Mills A, Schulman K, Fusco J, et al. Virologic Outcomes among Treatment-Naïve HIV+ Patients Initiating Common First Antiretroviral Therapy Core Agents in the OPERA Observational Database. Presented at: ISPOR 2019; New Orleans, LA, USA
An assessment of the impact of inhibition of tubular secretion of creatinine on the study of renal function
Brunet L, Hsu R, Mounzer K, et al. An assessment of the impact of inhibition of tubular secretion of creatinine on the study of renal function. Presented at: 23rd International Workshop on HIV and Hepatitis Observational Databases (IWHOD) 2019; Athens, Greece